ArticleJournal of clinical medicine research2026
Prescribing of GLP-1 and GIP/GLP-1 Receptor Agonists and Other Glucose-Lowering Drugs Requiring Special Caution in Elderly Japanese People With Type 2 Diabetes: A Preliminary Report.
Article in Journal of clinical medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adverse drug events are more common in elderly people, prompting the Japan Geriatrics Society to update its "Guidelines for Safe Pharmacotherapy in the Elderly" in 2025. In this revision, glucagon-like peptide-1 receptor agonist (GLP-1RA) and glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist (GIP/GLP-1RA) were newly added to the list of drugs requiring special caution. This study aimed to descriptively investigate real-world prescribing patterns of GLP-1RAs and their concomitant use with other glucose-lowering drugs (GLDs) requiring special caution among elderly people with type 2 diabetes (T2D). Methods: This single-center, retrospective, cross-sectional, exploratory descriptive study included outpatients aged ≥ 65 years with T2D who received antihyperglycemic therapy between September and December 2025. Clinical characteristics, laboratory data, and prescription records were extracted from electronic medical records. Descriptive analyses were conducted stratified by GLP-1RA use (users vs. non-users) and by age categories (65 to < 75 years and ≥ 75 years). Results: Among 214 eligible people with T2D, 50 (23.4%) were prescribed GLP-1RAs. Among GLP-1RA users, 63.0% were classified as having obesity, and the mean number of concomitant GLDs was 3.2 ± 0.8. GLP-1RAs were often prescribed concomitantly with other GLDs requiring special caution in elderly people, including metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), sulfonylureas, and insulin. In age-stratified analyses, oral semaglutide and dulaglutide were the most prescribed GLP-1RAs among people aged ≥ 75 years. Conclusions: GLP-1RAs were prescribed to approximately one quarter of elderly people with T2D and were most commonly used in people with obesity and more complex glucose-lowering regimens. Their frequent concomitant use with other drugs requiring special caution underscores the complexity of pharmacological management in elderly people.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.